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Background: Statin therapy plays a pivotal role in stabilizing the plaque for unstable angina (UA) patients although
its mechanism(s) remains largely unexplored. Here we aim to identify microRNAs (miRNAs) mediating the protective
effect of statins in UA patients.
Methods: MiRNAs Array was carried out to compare the circulating whole blood miRNA profile of UA patients
treated with (n = 10) and without statin (n = 10) and plasma miRNA profile UA patients treated with (n = 5) and
without statin (n = 5). 22 whole blood miRNAs and 19 plasma miRNAs were found significantly upregulated in
statin group. Targets of these miRNAs were predicted by algoritms: Targetscan, Miranda and Diana microT, then
clustered according to functions and cell types by using the Database for Annotation, Visualization and Integrated
Discovery (DAVID). To reveal the enriched function pathways in human atherosclerotic plaque, we analyzed
microarray data from GEO database, Coronary atherosclerotic plaque (n = 80); macrophages in ruptured plaque (n = 11);
carotid atheroma plaque (n = 64); advanced carotid atherosclerotic plaque (n = 29) using Reactome database.
Integrated analysis indicated that statin induced miRNAs mainly regulate the signaling pathways of Rho GTPase and
hemostasis in human atherosclerotic lesion. In vulnerable plaque, additional immune system signaling was also
targeted.
Results: The data showed target genes regulated by these statin induced miRNAs majorly expressed in i) plaque
macrophage and platelet, where they were involved in hemostasis process; ii) in monocyte to regulate NGF apoptosis;
iii) and in endothelial cell function in Rho GTPase pathway. Integrate analysis indicated that statin induced miRNAs
mainly regulate the signaling pathways of Rho GTPase and hemostasis in human atherosclerotic lesion.
Conclusions: Our study suggest that statin induces the expression of multiple miRNAs in the circulation of UA patient,
which play important roles by regulating signal pathways critical for the pathogenesis of UA.
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Acute coronary syndrome is the main cause of mortality
in the world. Statins are the major prescribed medication
for hyperlipidemia, and are also used in the primary and
secondary prevention of coronary artery disease. Its
main pharmaceutic effect is to inhibit 3-hydroxy-3-
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unless otherwise stated.which improves the prognosis of patients. Recently, sev-
eral experimental and clinical evidences have indicated
that statin can also function in cholesterol independent
ways [1,2]. For example, it can exert beneficial effect by
enhancing endothelial function, suppressing inflammation,
improving plaque stability, reducing hemostasis etc. [3,4].
Molecular mechanisms behind the pleiotropic effects of
statin, especially in multi-cells and in multi-signaling
pathways need to be further investigated. Moreover the
post-translation regulation and its functional network
during the process remain enigmatic.is an Open Access article distributed under the terms of the Creative Commons
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can regulate genes via post-translation inhibition by
incorporating into the RNA induced silencing complex
(RISC) and binding to the 3’ untranslated region
(3’UTR) of target mRNAs [5]. Recent studies have dem-
onstrated that miRNAs play important roles in several
cardiovascular disorders. miRNAs are also involved in
the pathogenesis of plaque lesions, such as to inhibit sta-
bility of neointima formation and to decrease the size of
plaque, and regulate neovasculartization [6-8].
Notably, statin may exert its effect though the down-
stream signaling pathway via regulating miRNA expres-
sion [5]. To study the miRNAs affected by statin
treatment, as well as the related gene networks regulated
by these miRNAs, we characterized the dynamic change
of circulation miRNAome for the UA patients after
using miRNA Taqman Low Density Array. Furthermore,
bioinformatics analyses were preformed to predict gene
targets for these differentially expressed miRNA and to
systematically analyze potential function(s) of miRNAs




Whole blood samples were collected from UA patients
(n = 30) enrolled at Peking University People’s Hospital.
The protocols were approved by the ethics review board
of Peking University People’s Hospital. Informed consent
was obtained from each participant. Diagnosis of UA
was made according to the ACC/AHA 2007 guidelines
for the management of patients with unstable angina/
non-ST-Elevation myocardial infarction and the ACC/
AHA/ACP-ASIM 1999 guidelines for the management
of patients with chronic stable angina. The patients
presenting elevated level of troponin I (TNI) and/or
creatine kinase (CK-MB), a history of severe hepatic
dysfunction, renal dysfunction, leukemia, leukopenia,
thrombocytopenia, ongoing inflammatory and malignant
diseases were excluded.
Whole blood and plasma sample collection and RNA
extraction
Whole blood samples were collected into PAXgene
tubes (PreAnalytiX). Blood samples were centrifugation
at 1,200 g for 10 minutes at 4°C, plasma were collected
from the supernatant then transferred to RNase-free
tubes. Samples were store at −80°C right after collec-
tion.. The RNA was isolated by using preanalytix kit
(Qiagen & BD company). Briefly, the pellet centrifuged
for 10 min at 3000 g, and resuspended in 350 μl buffer
BM1. 40 μl proteinase K and Buffer BM2 were added
and incubation continued for 10 min at 55°C. Then
transferred to PAXgene Shredder spin column andcentrifuged for 3 min at 15,000 g. Supernatant of flow-
through was transferred to microcentrifuge tube, and
700 μl isopropanol was added. The supernatant was loaded
on PAXgene RNA spin column to bind total RNA. The
total RNA was washed with buffer BM3, and DNA was
digested with 10 μl DNaseI. RNA was washed with buffer
BM3 and buffer BM4, eluted with Buffer BR5, and finally
stored at −70°C. Quality of the RNA samples was analyzed
by thermo multiskan FC (Thermofisher scientific).
MicroRNAs Taqman low density array
15 ng of total RNAs were reverse transcribed using the
Taqman miRNA reverse transcription kit with Taqman
miRNA Multiplex RT assays (human pool) (Applied Bio-
systems, Foster City, CA, USA). The pre-amplification
reaction products were then analyzed using Human
MicroRNA TaqMan Low Density Arrays (TLDA) version
3.0 (Applied Biosystems). MiRNA expressions were nor-
malized to the expressions of mammal U6, which
remained constant in all the samples among different
patient groups. Relative quantification software DataAs-
sist was used to calculate miRNAs expression difference
with comparative Ct method To find consistently differ-
entially expressed miRNAs, the data were subjected to
significance analysis of microarrays (SAM). MiRNAs
with q value <0.0001% were considered to be differentially
expressed.
Bioinformatic analyses
The bioinformatic work flow of the study is summarized in
supplement Figure 1. miRNA tissue expression profile was
retrieved from miRWalk common organ target tools
http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/ [9].
Target prediction of miRNAs was performed by using
three algorithms, TargetScan, miRanda and Diana-
microT [10-12].
For these target genes, we classified them according to
the cell type and their known functions by using Database
for Annotation, Visualization and Integrated Discovery
(DAVID) bioinformatics resources 6.7 http://david.abcc.
ncifcrf.gov [13]. Clustering of target genes according to
cell types were based on CGAP SAGE tissue-specific
library [14]. The pathway enrichment analysis was done
using reactome database [15]. To visualize the miRNAs
targeted genes and cell specific functional pathways, we
input network dataset into CytoScape version 3.0.0 beta 1
available at http://www.cytoscape.org [16].
To perform a integrated analysis of the miRNA involved
in atherosclerotic lesions, we downloaded the following
microarray data from the Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo/) [17]:
microarray data of macrophages from human ruptured
plaque and stable plaque (GSE41571), coronary athero-
sclerotic artery and internal mammary artery IMA
Figure 1 MiRNA targeted signaling pathways in four different important cells including plaque macrophage, platelet, monocyte and
endothelial cell. Bioinformatic analysis was used to find significantly upregulated miRNAs target genes. Those target genes were clustered based
on SAGE genie and categorized into four cell types. Each cell specific genes were then functionally clustered according to Reactome pathway.
The two steps were performed in DAVID functional clustering tools and the figure was generated using CytoScape. The pathway which was
targeted by only one miRNA was not displayed.
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(GSE28829) [19], distant macroscopically intact tissue ver-
sus atheroma plaque (GSE43292) [20]. The raw data were
analyzed by SAM and the significant differentially
expressed genes (FDR < 0.05) were selected for further
analysis. DAVID was used to analysis these genes’ enriched
pathway with Reactome database. The network of inte-
grated miRNA targets and plaque lesions upregulated
gene enriched pathway were illustrated by CytoScape ver-
sion 3.0.0 beta 1.
Results
Statin treatment changed miRNAome in the circulation of
UA patients
MicroRNA TLDA was performed to compare miRNA
expression profiles in the whole blood samples from UA
patients treated with (n = 10) or without statin (n = 10)
and plasma samples from UA patients treated with (n = 5)
or without statin (n = 5). For these two groups of patients,
no significant differences were observed in baseline
conditions, medical histories, medications and the results
of laboratory testings (Table 1). The miRNAs expression
profiles were significantly different between these two
groups (FDR < 0.001%) and 22 whole blood miRNAs and19 plasma miRNAs were found significantly upregulated
in the statin treatment group compared with the control
group (Table 2). The whole analysis flow was presented in
diagram. (Additional file 1: Figure S1) MiRNAs profile of
the statin treatment group and the control group were
illustrated in heatmap (Additional file 2: Figure S2).
Identification of the cell origins of statin induced
circulating miRNAs
To reveal the possible cell/tissue origin(s) for these dif-
ferentially expressed circulating miRNAs, we searched
miRWalk database for the organs which could express
these microRNAs. We found that mir-15b, mir-150,
mir-19b, mir-106a, mir-222, mir223, mir-26a, mir-30c,
mir-451 and mir-92a were reported exist in monocyte.
Mir-15b, mir-106a, mir-150, mir-191, mir-26a, mir-222,
mir-223, mir-30b, mir-451, mir-92a and mir-93 can be
expressed by macrophage. Mir-15b, mir-150, mir-223
mir-30b, mir-30c and mir-451 exist in platelet etc. In
plasma, these MiRNAs were reported exited in mono-
cyte mir-21, mir-24, mir-146b, mir-142-3p, mir-126,
mir-20a, mir-146a, mir-222, mir-223, mir-19b, mir-451,
mir-106a and mir-92a. mir-21, mir-17, mir-24, mir-
146b, mir-142-3p, mir-19a, mir-126, mir-20a, mir-146a,
Table 1 Characteristics of the study population treated with and without statin
Whole blood Plasma
Control(n = 10) Stain(n = 10) p value Control(n = 5) Stain(n = 5) p value
General data
Sex, M/F (4/6) (5/5) >0.99 (3/2) (1/4) 0.524
Age(yrs) 59 ± 7.9 56 ± 7.6 0.394 59 ± 4.2 64 ± 9.9 0.343
SBP(mm Hg) 135 ± 15.1 131 ± 15.6 0.889 131 ± 12.1 128 ± 16.4 0.758
DBP(mm Hg) 80 ± 7.1 82 ± 12.4 0.591 78 ± 8.1 75 ± 11.2 0.669
Medical history
Hypertension(%) 90(9/10) 80(8/10) >0.99 60(3/5) 100(5/5) 0.444
Diabetes(%) 0(0/10) 0(0/10) >0.99 20(1/5) 20(1/5) >0.99
Hyperlipaemia(%) 30(3/10) 50(5/10) 0.649 60(3/5) 100(5/5) 0.444
Cerebral vascular disease (%) 0(0/10) 0(0/10) >0.99 0(0/5) 0(0/5) >0.99
Smoking(%) 20(2/10) 0(0/10) 0.474 40(2/5) 0(0/5) 0.444
Laboratory test
Glucose(mmol/l) 5.4 ± 1.2 5.2 ± 1.4 0.796 4.8 ± 0.6 5.1 ± 0.6 0.526
LDL cholesterol (mmol/l) 2.5 ± 0.9 2.2 ± 0.9 0.577 2.6 ± 0.7 2.4 ± 0.4 0.605
HDl cholesterol (mmol/l) 1.0 ± 0.1 1.1 ± 0.3 0.314 1.2 ± 0.3 0.8 ± 0.1 0.034*
TC (mmol/l) 4.3 ± 0.9 4.0 ± 1.1 0.364 4.3 ± 0.5 3.9 ± 0.6 0.462
TG(mmol/l) 1.3 ± 0.6 1.2 ± 0.7 0.496 1.6 ± 0.2 1.6 ± 0.3 0.897
Creatinine(mg/dl) 60.7 ± 13.5 62.5 ± 18.8 0.781 76.2 ± 13.5 62.0 ± 20.2 0.781
alt(u/l) 28.9 ± 16.8 20.7 ± 9.2 0.211 21.6 ± 17.2 17.6 ± 5.3 0.616
ast(u/l) 23.4 ± 11.2 18.1 ± 4.27 0.224 18.8 ± 8.3 18.4 ± 2.3 0.897
Medication
Aspirin(%) 30(3/10) 50(5/10) 0.649 40(2/5) 60(3/5) >0.99
Clopidogrel(%) 30(3/10) 30(3/10) >0.99 20(1/5) 60(3/5) 0.524
Calcium antagonists (%) 40(4/10) 20(2/10) 0.628 40(2/5) 20(1/5) >0.99
ACEI/ARBs(%) 50(5/10) 20(2/10) 0.349 0(0/5) 20(1/5) >0.99
β-Blockers(%) 20(2/10) 40(4/10) 0.628 40(2/5) 40(2/5) >0.99
SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TC, total cholesterol; TG, triglyceride; ALT,
alanine aminotransferase; AST, aspartate aminotransferase; ACEI, angiotensin-converting enzyme inhibitor; and ARB, angiotensin receptor blocker. Comparisons
between groups were performed with Student’s t test or Mann–Whitney U test for continuous variables and with the Fischer exact test or x2 test for categorical variables.
*p<0.05 versus control.
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(Additional file 3: Table S1). Thus, we can cluster these
statin regulated miRNAs according to their cell origins.
Signaling pathways regulated by statin induced whole
blood miRNAs
We predicted target genes regulated by these statin induced
miRNAs by using three public algorithms: TargetScan,
miRanda, and Diana-microT (Additional file 4: Table S2).
To analysis the mRNA targets calculated by the three tools,
we input each of 22 miRNA targets into DAVID bioinfor-
matic tools. In order to analysis the whole blood miRNA
specific in different cells. Target genes were separated into
groups using serial analysis of gene expression (SAGE)
database based on different cell types. We focused on ath-
erosclerosis related cells, including monocytes, plaquemacrophage, platelet, and endothelial cell. The target gene
enriched pathways were analyzed in each specific cell type
and visualized using cytoscape. We found that the target
genes regulated by statin induced miRNA were enriched in
the following pathways: (1) pathways of hemostasis, NGF
(Nerve Growth Factor), membrane trafficking, opioid and
PDGF (platelet-derived growth factor),in plaque macro-
phages; (2) pathways of hemostasis, Rho GTPases,
NGF, integrin cell surface interactions, insulin recep-
tor, and EGFR (epidermal growth factor receptor) in
platelet; (3) Monocyte related pathway of signaling by
NGF, Rho GTPases, apoptosis etc.; (4) Endothelial cell
related signaling by NGF, hemostasis, apoptosis, PDGF
etc. In general, the hemostasis pathway is the major
one in macrophage and platelet; the Rho GTPases
pathway is mainly regulated in monocyte and platelet
Table 2 Significant differentially expressed miRNA profile in UA patients treated with or without statin
Whole blood Score(d) Fold change q-value(%) Plasma Score(d) Fold change q-value(%)
hsa-miR-191 3.9826 2.0182 <0.0001% hsa-miR-21 4.0676 9.6700 <0.0001%
hsa-miR-92a 3.8634 2.6235 <0.0001% hsa-miR-223 3.4159 8.6072 <0.0001%
hsa-miR-532-3p 3.3904 2.4110 <0.0001% hsa-miR-106a 3.1782 5.9014 <0.0001%
hsa-miR-574-3p 3.1517 2.7277 <0.0001% hsa-miR-17 3.0701 5.7191 <0.0001%
hsa-miR-30b 3.0671 2.2520 <0.0001% hsa-miR-320 2.7697 7.9742 <0.0001%
hsa-miR-486-5p 3.0474 2.2180 <0.0001% hsa-miR-24 2.5543 5.1630 <0.0001%
hsa-miR-223 3.0328 2.3800 <0.0001% hsa-miR-146b-5p 2.4747 16.9902 <0.0001%
hsa-miR-30c 2.9640 2.1134 <0.0001% hsa-miR-142-3p 2.4040 16.8645 <0.0001%
hsa-miR-484 2.9314 2.4529 <0.0001% hsa-miR-19b 2.3810 7.1494 <0.0001%
hsa-miR-451 2.8041 3.1920 <0.0001% hsa-miR-19a 2.2580 9.1338 <0.0001%
hsa-miR-331-3p 2.6506 1.8440 <0.0001% hsa-miR-30a-5 2.1183 9.2122 <0.0001%
hsa-miR-25 2.6181 2.3039 <0.0001% hsa-miR-222 2.0399 8.4189 <0.0001%
hsa-miR-222 2.5022 2.0910 <0.0001% hsa-miR-126 2.0359 7.1429 <0.0001%
hsa-miR-652 2.4739 2.4337 <0.0001% hsa-miR-451 1.9745 9.8249 <0.0001%
hsa-miR-19b 2.4250 2.0244 <0.0001% hsa-miR-197 1.9738 2.7519 <0.0001%
hsa-miR-15b 2.2769 2.2809 <0.0001% hsa-miR-92a 1.9470 6.4763 <0.0001%
hsa-miR-140-3p 2.2018 1.9416 <0.0001% hsa-miR-20a 1.9312 6.8796 <0.0001%
hsa-miR-26a 2.1192 2.3774 <0.0001% hsa-miR-29a 1.8389 4.4884 <0.0001%
hsa-miR-324-3p 2.1131 1.8923 <0.0001% hsa-miR-146a 1.7932 7.7389 <0.0001%
hsa-miR-150 2.0946 1.7147 <0.0001%
hsa-miR-93 2.0697 2.4706 <0.0001%
hsa-miR-106a 2.0101 2.2727 <0.0001%
22 whole blood miRNAs and 19 plasma miRNAs were significantly different between the statin treatment group and the control group.
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lyzed here.
Chracterization of the pathways regulated by statin
induced miRNA in atherosclerosis plaque
To reveal the function of statin induced miRNA in ath-
erosclerotic plaque, we analyzed four microarray datasets
related to atherosclerosis from GEO database, and the
alteration of pathways in the atherosclerotic lesion group
were selected by enrich analysis of significant upregu-
lated gene (Additional file 5: Table S3). The statin upreg-
ulated miRNAs in whole blood and plasma exert its
pharmaceutical function by inhibit the upregulated gene
in lesions. To characterize the putative functions of the
miRNAs, we identified the genes that were upregulated
in the disease group. Then we generated the putative
function networks targeted by these statin induced
miRNAs in each of the four datasets. In the two coron-
ary artery datasets, the two networks indicated that
both type miRNAs majorly targeted the pathways of
Rho GTPases, hemostasis, EGFR, synaptic transmis-
sion and opioid signaling (Figure 2a, b). Other evi-
dence from the dataset of resident macrophage of
ruptured plaque is that both miRNAs target pathwaysmajor in NGF, Rho GTPases, hemostasis and membrane
trafficking (Figure 3a, b). In the two carotid athero-
sclerosis datasets, we also have miRNA target involved
pathway overlap with upregulated pathway in disease
status. The NGF signaling pathway, hemostasis and
Rho GTPase signaling also emerged in the carotid
plaque (Additional file 6: Figure S3a, b). The tagets
genes of statin induced miRNA target are also enriched
in the hemostasis and Rho GTPase signaling in the ad-
vanced carotid plaque (Additional file 7: Figure S4a, b).
Moreover, we combined the previous four miRNA
target networks (fig 3,4 supplement fig 3,4). Results indi-
cated that the whole blood miRNAs target Rho GTPase
and hemostasis which were commonly enriched in four
lesions (Figure 4a). The plasma miRNAs integrated net-
work the hemostasis and Rho GTPase pathway (Figure 4b).
These results indicated that statin upregulated miRNA
targets functionally enriched in the two pathways in the
disease status.
Statin induced miRNAand their targets in Hemostasis and
Rho GTPase pathways
From above analysis, hemostatsis and Rho GTPase ap-
peared to be two most important pathways targeted by
Figure 2 (See legend on next page.)
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Figure 2 MiRNA targeted the signaling pathways of upregulated genes in coronary atherosclerotic lesion. The data which compared
coronary atherosclerotic plaque and IMA (internal mammary artery) were obtained from GEO database. SAM was used to analyze the significantly
differentially expressed genes (FDR<0.05). Those genes enriched pathways and miRNA target gene pathways were clustered by DAVID based on
Reactome pathway. A: Whole blood miRNAs target pathways. B: plasma miRNAs target pathways. Illustration combined the miRNA target
pathways which were also involved in the coronary atherosclerosis plaque.
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further analyze these two pathways. We made a net-
work of miRNAs and their targets in hemostasis path-
way (Figure 5a, b), showing that both whole blood and
plasma miRNAs target genes were mainly involved in
interactions of cell surfaces on the vascular wall, plate-
let activation signaling and aggregation. On the other
hand, in Rho GTPase signaling pathway, whole blood
and plasma miRNAs targeted both the activator GEFS
and inactivator GAPs and GDIs of the Rho GTPase.
Furthermore the downstream effectors of the pathway
were also targeted by certain miRNAs (Figure 6a, b).
Discussion
The benefits of Statins were caused by the inhibition of
hydroxy-methyl-glutaryl-CoA (HMGCoA) reductase. Des-
pite of the cholesterol lowering effect that ameliorated
atherosclerotic plaque progression and reduced the ad-
verse events in patients, accumulated evidence also
showed that statins exerted pleiotropic effects [4,21-25].
In our study, the upregulated miRNAs downstream target
in the specific cells most focused on the signaling pathway
of NGF, Hemostasis, Rho GTPase and etc. As the circulat-
ing miRNAs could exert post-translation regulation in the
target tissue, we preformed the miRNA and mRNA inte-
grated analysis to describe statin induced miRNA function
related to vascular disease. Previous studies have noticed
the circulating microRNA have association with vascular
disease [26,27]. We have analyzed the statin induced
miRNAs which targeted the certain pathways, including
the hemostasis, RhoGTPase and pathway in NGF rear
reported in the atherosclerosis. Interestingly, our re-
sults are in accord with some previous findings such as
hemostatsis and rho kinase pathway [28,29]. From the
systematic aspect, our bioinformatic findings and func-
tional predictions could explain the novel mechanism
by which miRNAs regulated post-translational repression
of certain biologic process.
Several clinical and basic studies suggested that statin
had non-cholesterol-dependent effect on hemostasis. For
example, The PROVE-IT (Pravastatin or Atorvastatin
Evaluation and Infection Therapy) trial investigated high
doses of statins in 4162 patients with acute coronary
syndromes. The beneficial effect was independent of
baseline LDL cholesterol and reached statistical signifi-
cance [30]. In the JUPITER trial, rosuvastatin therapy
was associated with decreased venous thromboembolismremarkably [31]. In a meta-analysis of the previous stud-
ies to investigate the efficacy of the immediate adminis-
tration of statins in patients with acute coronary
syndrome [32], the early beneficial effect was seen within
acute phase (1 month). The significant reduction in clin-
ical outcomes was associated with statin treatment,
which played a potential role in antithrombosis. In
mouse model, atorvastatin demonstrated an anticoagula-
tion effect, which was induced by the reduction of plate-
let activation through upregulation of eNOS [33,34]. The
abrupt withdrawal of statin abrogates the beneficial
effect on endothelial function [4]. Furthermore, statins
reduced tissue factor expression in macrophages and
thereby inhibited the thrombotic interactions of the vas-
cular wall [35]. We have noticed that the miRNA mostly
inhibited the targets of hemostasis according to the bio-
informatic analysis. It suggests that statin may act as an
anticoagulant agent by increasing certain miRNA to in-
hibit coagulation. The specific aspect of miRNAs plays
an important role in the process were mainly in signal-
ing of the platelet activation and aggregation, and cell
surface interactions on the vascular wall.
Meanwhile the association between Rho pathway and
atherosclerotic lesions has long been studied. As the
effectors of the small GTPase Rho, ROCKs have been
shown to be upregulated in inflammatory arteriosclerotic
lesions and to cause coronary vasospastic responses
through inhibition of MLCP in both a porcine model of
coronary artery spasm [36] and arteriosclerotic human
arteries [37]. It has been suggested that ROCK induced
NF-κB activation and subsequent T lymphocyte prolifer-
ation, which contributed to the development of early
atherosclerosis [38]. Long-term inhibition of ROCKs
caused a suppression of coronary arteriosclerosis and ab-
rogation of coronary vasospastic activities in pig [39]. All
the studies suggested that Rho GTPase signaling plays
an important role in atherosclerosis, which was further
demonstrated by our results that miRNA targeted the
upregulated Rho GTPase pathway of coronary athero-
sclerotic plaque and ruptured plaque. Moreover,
ROCK1-deficiency mice in bone-marrow-derived cells
exhibited a phenotype of decreased plaques size in LDL-
receptor deficient background [4]. ROCK1 is predomin-
antly upregulated in macrophages that were activated
and adherent to endothelial cells during atherosclerosis.
ROCK1-deficient macrophages decreased chemotaxis,
cholesterol uptake, and foam-cell formation, which
Figure 3 MiRNA targeted the signaling pathways of upregulated genes from macrophages in ruptured atherosclerotic plaque. The data
which compared macrophage in ruptured atherosclerotic plaque with in stable plaque were obtained from GEO database. SAM was used to
analyze the significantly differentially expressed genes (FDR<0.05). Those genes enriched pathways and miRNA target gene pathways were
clustered by DAVID based on Reactome pathway. A: Whole blood miRNAs target pathways. B: plasma miRNAs target pathways. Illustration
combined the miRNA target pathways which were also involved in the coronary atherosclerosis plaque.
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Figure 4 Intersection network of the miRNA target pathway network. The illustrated network was generated from the data of the miRNA
target pathways in coronary atherosclerotic plaque, ruptured coronary plaque, carotid plaque and advanced carotid plaque. A. The network
showed that the whole blood miRNA targeted Signaling by Rho GTPases and Hemostasis in the four atherosclerotic lesion. B. The network
showed that the plasma miRNA targeted Signaling by Hemostasis and Rho GTPases in four atherosclerotic lesions.
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study suggested that circulating miRNA, which targeted
Rho GTPase signaling, may also inhibit the plaque
lesion. Thus, the anti-arteriosclerotic effect of statin may
be partly due to the prevention of the activation of
downstream Rho targets such as ROCKs [35]. Fluvastatin
inhibited Rho in rat vascular smooth muscle cells, leading
to the upregultion of iNOs expression [41]. Indeed, statins
have been shown to inhibit Rho isoprenylation and ROCK
activity. Statins can inhibit mevalonate synthesis, prevent
membrane interaction of Rho, and suppress its subsequent
activation of ROCKs [42]. Here we have provided a newaspect that miRNA reduced the RhoGTPase. MiRNA re-
pressed target Rho GTPase signaling pathway involved in
the plaque rupture. We showed that inhibition of Rho
GTPase pathway appeared important in monocyte. There-
fore, it is interesting to speculate whether some of the
clinical benefits of statin therapy could be mediated by
miRNA induced inhibition of the Rho GTPase pathways.
So the miRNA induced inhibition of the effectors of the
downstream may explain how statin have the effect on
atherosclerosis.
On the other hand, the NGF signaling pathway and
opioid pathway in our study are relatively new signaling
Figure 5 (See legend on next page.)
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Figure 5 MiRNA targeted upregulated genes related with hemostasis in plaque. MiRNA targets were predicted by targetscan, Miranda and
DIANAmT. The coronary plaque microarray data were analyzed by SAM and significantly differentially expressed genes were input into DAVID to
select the hemostasis related genes. After integration of the miRNA targets genes and hemostasis related genes in the coronary plaque data, the
miRNA target network was created to illustrate the mechanism how miRNAs were involved in the development of plaque. A: the network of
whole blood miRNAs target genes. B: the network of plasma miRNAs target genes. The names of genes were official gene symbols. MicroRNAs
with red border line are the miRNAs presents in the former network target the hemostasis. The yellow nodes are related with signaling of platelet
activation and aggregation. The green nodes are related with formation of fibrin clot. The purple nodes are related with dissolution of fibrin clot.
The blue nodes are related with cell surface interactions on the vascular wall.
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the survival, differentiation and plasticity of neurons in
the peripheral and central nervous system, and opioid
pathway has powerful analgesic and sedative effects.
These two signaling pathways exert important function
in the signal transmission in neurons. However, studies,
which investigated these two pathways in atherosclerosis
were rear. NGF molecules decreased in the human cor-
onary atherosclerotic plaque [43], and also reduced in
the plasma of ACS patients [44]. The NGF signaling
pathway, which was targeted by miRNA, may be also
involved in the intervention of diseases. The pain of pa-
tients could be influenced by statin regulated miRNAs,
which target in the opioid pathway. Further study is
needed to unveil the potential effect of statin.
In summary, the combined data mining of miRNA
and mRNA expression provided a putative mechanism
to explain partial effect of statin that has been noticed.
Conclusions
MiRNAs array indicated that statin induced 22 miRNAs
in whole blood and 19 miRNAs in plasma. Bioinformatic
analysis of the miRNAs signature revealed that statin in-
fluenced different pathways in the atherosclerosis related
cells. Together with data from atherosclerosis lesions,
miRNAs were also involved in the development of ath-
erosclerotic lesion by targeting Hemosatsis and Rho
GTPase pathway. All the results provided systematic evi-
dence for regulatory effect of statin in unstable angina
patients. Bioinformatic analysis was used to find signifi-
cantly upregulated miRNAs target genes. Those target
genes were clustered based on SAGE genie and catego-
rized into four cell types. Each cell specific genes were
then functionally clustered according to Reactome path-
way. The two steps were performed in DAVID func-
tional clustering tools and the figure was generated
using CytoScape. The pathway which was targeted by
only one miRNA was not displayed.
The data which compared coronary atherosclerotic
plaque and IMA (internal mammary artery) were obtained
from GEO database. SAM was used to analyze the signifi-
cantly differentially expressed genes (FDR < 0.05). Those
genes enriched pathways and miRNA target gene path-
ways were clustered by DAVID based on Reactomepathway. A: Whole blood miRNAs target pathways. B:
plasma miRNAs target pathways. Illustration combined
the miRNA target pathways which were also involved in
the coronary atherosclerosis plaque.
The data which compared macrophage in ruptured ath-
erosclerotic plaque with in stable plaque were obtained
from GEO database. SAM was used to analyze the signifi-
cantly differentially expressed genes (FDR < 0.05). Those
genes enriched pathways and miRNA target gene path-
ways were clustered by DAVID based on Reactome path-
way. A: Whole blood miRNAs target pathways. B: plasma
miRNAs target pathways. Illustration combined the
miRNA target pathways which were also involved in the
coronary atherosclerosis plaque.
The illustrated network was generated from the data of
the miRNA target pathways in coronary atherosclerotic
plaque, ruptured coronary plaque, carotid plaque and
advanced carotid plaque. A. The network showed that
the whole blood miRNA targeted Signaling by Rho
GTPases and Hemostasis in the four atherosclerotic
lesion. B. The network showed that the plasma miRNA
targeted Signaling by Hemostasis and Rho GTPases in
four atherosclerotic lesions.
MiRNA targets were predicted by targetscan, Miranda
and DIANAmT. The coronary plaque microarray data
were analyzed by SAM and significantly differentially
expressed genes were input into DAVID to select the
hemostasis related genes. After integration of the
miRNA targets genes and hemostasis related genes in
the coronary plaque data, the miRNA target network
was created to illustrate the mechanism how miRNAs
were involved in the development of plaque. A: the net-
work of whole blood miRNAs target genes. B: the network
of plasma miRNAs target genes. The names of genes were
official gene symbols. MicroRNAs with red border line are
the miRNAs presents in the former network target the
hemostasis. The yellow nodes are related with signaling of
platelet activation and aggregation. The green nodes are
related with formation of fibrin clot. The purple nodes are
related with dissolution of fibrin clot. The blue nodes are
related with cell surface interactions on the vascular wall.
MiRNA target was predicted by targetscan, Miranda
and DIANAmT. The ruptured plaque microarray data
were analyzed by SAM, and significantly differentially
Figure 6 MiRNA targeted upregulated genes of Rho GTPase signaling. MiRNA target was predicted by targetscan, Miranda and DIANAmT.
The ruptured plaque microarray data were analyzed by SAM, and significantly differentially expressed genes were input into DAVID to select the
hemostasis related gene. The miRNA targets and Rho GTPase related genes were integrated. A: the network of whole blood miRNAs target
genes. B: the network of plasma miRNAs target genes. The names of genes were official gene symbols. MicroRNAs with red border line are the
miRNAs presents in the former network target the Rho GTPase pathway. The green node represents activation of Rho GTPase GDP by GEFS. The
brown node represents activation of stream effector by Rho GTPase GTP. The blue node represents inactivation of Rho GTPase GTP by GAPs
through hydrolysis. The purple node represents inactivation of Rho GTpase GDP by GDIs.
Li et al. BMC Medical Genomics  (2015) 8:12 Page 12 of 14
Li et al. BMC Medical Genomics  (2015) 8:12 Page 13 of 14expressed genes were input into DAVID to select the
hemostasis related gene. The miRNA targets and Rho
GTPase related genes were integrated. A: the network of
whole blood miRNAs target genes. B: the network of
plasma miRNAs target genes. The names of genes were
official gene symbols. MicroRNAs with red border line
are the miRNAs presents in the former network target
the Rho GTPase pathway. The green node represents
activation of Rho GTPase GDP by GEFS. The brown
node represents activation of stream effector by Rho
GTPase GTP. The blue node represents inactivation of
Rho GTPase GTP by GAPs through hydrolysis. The
purple node represents inactivation of Rho GTpase
GDP by GDIs.
Additional files
Additional file 1: Figure S1. Study work flow diagram. Whole blood
samples were collected from UA patients (n = 30) enrolled at Peking
University People’s Hospital. TLDA, TaqMan Low Density Arrays; SAM,
Significance Analysis of Microarrays; CGAP SAGE, Cancer Genome
Anatomy Project Serial Analysis of Gene Expression; GEO, Gene
expression Omnibus.
Additional file 2: Profile of circulating miRNAs in non-statin group
and statin group. A: Whole blood differential miRNAs profiles. B: plasma
miRNAs differential miRNAs profiles. Heatmap displays the levels of
significantly differential expressed miRNAs. Color intensity represents the
expression value in each row, bright red indicates the high expression
level and the bright green indicates the low expression level.
Additional file 3: Table S1. MiRNAs organ expression profile were
generate from miRWalk database. The organ expression profiles of the
miRNAs were based on published data.
Additional file 4: Table S2. Enriched pathways of the MiRNAs’ target
genes. Target genes list of significant differential MiRNAs predicted by
TargetScan, miRanda, and Diana-microT.
Additional file 5: Table S3. Enriched pathways of upregulated genes in
atherosclerosis lesions.
Additional file 6: Figure S3. MicroRNA target signaling pathway in the
human cartoid plaque. The data which compared human carotid plaque
and intact carotid tissue were obtained from GEO database. SAM was
used to analyze the significantly differentially expressed genes (FDR < 0.05).
Those genes enriched pathways and miRNA target gene pathways were
clustered by DAVID based on Reactome pathway. A: Whole blood miRNAs
target pathways. B: plasma miRNAs target pathways. Illustration combined
the miRNA target pathways which were also involved in the coronary
atherosclerosis plaque.
Additional file 7: Figure S4. MicroRNA target signaling pathway in the
human advance carotid plaque. The data which compared advance
carotid plaque and early carotid plaque were obtained from GEO database.
SAM was used to analyze the significantly differentially expressed genes
(FDR < 0.05). Those genes enriched pathways and miRNA target gene
pathways were clustered by DAVID based on Reactome pathway. A: Whole
blood miRNAs target pathways. B: plasma miRNAs target pathways.
Illustration combined the miRNA target pathways which were also involved
in the coronary atherosclerosis plaque.
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